Status:
UNKNOWN
Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts
Lead Sponsor:
Assiut University
Conditions:
Common Wart
Eligibility:
All Genders
18-40 years
Phase:
PHASE3
Brief Summary
The investigate the efficacy and safety of combined 'cryo-immuno-therapy' versus intralesional tuberculin purified protein derivative (PPD) antigen immunotherapy alone for multiple common warts
Detailed Description
Common warts are benign skin lesions caused by the human papillomavirus (HPV). The dorsal surface of the hands and fingers are the main predilection sites. Cryotherapy is frequently used to eradicate ...
Eligibility Criteria
Inclusion
- A dults older than 18 years
- multiple (\>3 warts) common warts .
- not currently using other treatments for a wart .
- not had relapsed at least once after treatment with any of the tissue-destructive modalities.
- Positive tuberculin skin test.
Exclusion
- Acute febrile illness, history of asthma, allergic skin disorders.-1 2- Pregnancy or lactation. 3- Cold-induced diseases. 4- Immunosuppression.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04288817
Start Date
March 1 2020
End Date
May 1 2021
Last Update
February 28 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.